Clinical Trials
3 trialsNCT00095979 2019-07-24
Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00883116 2017-03-09
IXAMPLE2
R-Pharm
Phase 3 Terminated
NCT01454479 2011-10-19
A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma
Chang Gung Memorial Hospital
Phase 1 Unknown